Cas:4387-36-4 2-Iodobenzonitrile manufacturer & supplier

We serve Chemical Name:2-Iodobenzonitrile CAS:4387-36-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-Iodobenzonitrile

Chemical Name:2-Iodobenzonitrile
CAS.NO:4387-36-4
Synonyms:2-Iodobenzonitrile;MFCD00079761;1-Cyano-2-iodobenzene;Benzonitrile, 2-iodo-;ortho-iodobenzonitrile;2-iodobenzenecarbonitrile;o-iodobenzonitrile;Benzonitrile,2-iodo;2-cyano-1-iodobenzene;2-acetylbenzonitrile
Molecular Formula:C7H4IN
Molecular Weight:229.018
HS Code:2926909090

Physical and Chemical Properties:
Melting point:52-54°C
Boiling point:283.1±23.0 °C at 760 mmHg
Density:1.9±0.1 g/cm3
Index of Refraction:1.661
PSA:23.79000
Exact Mass:228.938828
LogP:2.49

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:3439
Packing Group:


Contact us for information like 2-Iodobenzonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-acetylbenzonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzonitrile,2-iodo Use and application,MFCD00079761 technical grade,usp/ep/jp grade.


Related News: Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector. 2-Iodobenzonitrile manufacturer The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself. 2-Iodobenzonitrile supplier Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells. 2-Iodobenzonitrile vendor The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself. 2-Iodobenzonitrile factory Advanced clinical trials with the Company��s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.